BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|March 2, 2004
- Pharmaceutical Technology-03-02-2004
- Volume 28
- Issue 3
Stakes Getting Higher for Contractors
Author(s)Jim Miller
As outsourcing services become a more integral part of pharmaceutical processes, drug companies are taking a harder line on consequential.
Advertisement
Articles in this issue
over 22 years ago
Pharmaceutical Pricing and Healthcare Accessover 22 years ago
The Effect of Buffers on Protein Conformational Stabilityover 22 years ago
Packaging Helps Protect Temperature-Sensitive Productsover 22 years ago
Resealed Erythrocytes: A Reviewover 22 years ago
Pharma Industry Drives Innovation in Barrier/Isolation Designover 22 years ago
Connecting Clinical Trial Management to Pharmaceutical Manufacturingover 22 years ago
March 2003Advertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI Formulation: Regulators Want Data
2
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
3
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
4
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
5